Mats Hellström

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer

Theodoros Foukakis, Gϋnter von Minckwitz, Nils‐Olof Bengtsson et al. · JAMA · 2016 · 100 citations

Medicine, Oncology, Pharmacology +17

Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial

Siker Kimbung, Ida Markholm, Judith Bjöhle et al. · International Journal of Cancer · 2017 · 80 citations · Full text

Medicine, Oncology, Pharmacology +16

Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres

Wolfgang Kuchinke, Christian Ohmann, Qin Yang et al. · Trials · 2010 · 64 citations · Full text

Health Professions, Clinical Sciences, Health Informatics +13

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer

Thomas Hatschek, Theodoros Foukakis, Judith Bjöhle et al. · JAMA Oncology · 2021 · 56 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

Alexios Matikas, Hemming Johansson, Per Grybäck et al. · Clinical Cancer Research · 2022 · 41 citations

Medicine, Immunology, Oncology +17